--- title: "Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: cost-effectiveness analyses and utility weights" description: "Published cost-effectiveness analyses and health-state utility weights for Anaphylm (dibutepinephrine, AQST-109) in Type I allergic reactions including anaphylaxis, each value quoted from the article: 11 cost-effectiveness analyses and 9 studies reporting utility weights. Analyses: Intranasal or sublingual and inhaled epinephrine versus intramuscular epinephrine for severe allergic reactions in peanut allergy, United States: Shaker et al. (2025); Personal epinephrine autoinjectors versus no personal epinephrine in children with peanut allergy, United States: Shaker and Greenhawt (2018a); Universal prescription of two epinephrine autoinjectors versus risk-stratified prescription in peanut allergy, United States and United Kingdom: Shaker et al. (2021a); Undesignated school stock epinephrine (supplemental and universal models) versus no school supply for peanut anaphylaxis, United States: Shaker and Greenhawt (2019a); 7 further articles. Utility weights: Utility weights for moderate and severe allergic reactions, food allergy, and anaphylaxis, peanut allergy: Shaker et al. (2021a); Utility weights for peanut allergy, anaphylaxis, and oral immunotherapy, peanut allergy: Shaker et al. (2021b); Baseline utility weight, peanut allergy: Shaker et al. (2025); Disutility for food allergy, peanut allergy in school-age children: Shaker and Greenhawt (2019a); 5 further articles. Every value is a verbatim quote from the primary article it is shown with." canonical: "https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/cost-effectiveness-analyses" published: "2026-10-22T07:49:06-04:00" modified: "2026-10-22T07:49:06-04:00" --- # Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: cost-effectiveness analyses and utility weights Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles. ## Overview | Item | Detail | | --- | --- | | Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. | | Cost-effectiveness analyses | 11 | | Studies reporting utility weights | 9 | ## 1 Cost-effectiveness analyses ### 1.1 Analyses of Anaphylm (dibutepinephrine and AQST-109) No evidence found. ### 1.2 Treatments for the same indication #### Intranasal or sublingual and inhaled epinephrine versus intramuscular epinephrine for severe allergic reactions in peanut allergy, United States: Shaker et al. (2025) Relevance: Evaluates non-injectable epinephrine, modeled as an approved intranasal form or a sublingual form under development, against intramuscular epinephrine for severe allergic reactions in peanut allergy in the United States; section 4.1 quotes this analysis and reports that no economic model of dibutepinephrine sublingual film has been identified. > “Markov cohort analyses evaluated the cost-effectiveness of noninjectable epinephrine forms.” > “The base-case assumed exaggerated anaphylaxis fatality rates (50-fold increase) for using inhaled epinephrine given low certainty evidence in anaphylaxis and deliberately reduced fatality risk for nasal or sublingual forms (10-fold reduction) theorizing higher adherence and early use during an allergic reaction.” > “In the base-case scenario, assuming a 10-fold decreased risk in peanut allergy fatality associated with intranasal or sublingual epinephrine treatment for a severe allergic reaction (net monetary benefit [NMB], $2,189,134) vs intramuscular epinephrine use (NMB, $2,189,114), intranasal or sublingual epinephrine was the most cost-effective option (incremental cost-effectiveness ratio [ICER], $83,748/quality-adjusted life-year [QALY]), but only at a marginal annual cost of $4.” > “Intramuscular epinephrine was cost-effective (ICER, $17,900/QALY) vs inhaled epinephrine (NMB, $2,183,531), although inhaled epinephrine reached cost-effectiveness (willingness to pay [$100,000/QALY]) if associated fatality risk fell below 2.5-fold.” > “Substituting a single noninjectable form of epinephrine for a second injectable device (in patients prescribed 2 autoinjectors already) would be cost-effective; however, adding a supplemental noninjectable device was not cost-effective, even assuming a 10-fold risk reduction with multiple device carriage (ICER, $858,462).” Source: [Shaker et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39637974/) #### Personal epinephrine autoinjectors versus no personal epinephrine in children with peanut allergy, United States: Shaker and Greenhawt (2018a) Relevance: Estimates the value-based price of epinephrine auto-injectors for children with peanut allergy in the United States as a function of fatality risk, the auto-injector pricing analysis section 4.1 cites. > “In an economic evaluation study using a cost-effectiveness birth cohort model over an extended 80-year time horizon, Markov simulations of children with peanut allergy evaluated cost ceilings for value-based epinephrine prices in peanut allergy.” > “All costs were expressed in 2018 US dollars and discounted at 3% per annum.” > “Cohorts of children with peanut allergy prescribed epinephrine autoinjectors were compared with those not receiving personal epinephrine prescriptions. Children without epinephrine autoinjectors assumed 10-fold to 100-fold fatality risk increases. Costs were evaluated from a societal perspective.” > “Over the time horizon, the cost of anaphylaxis preparedness and treatment in those with personal epinephrine devices was $25 478 (95% CI, $25 399-$25 557) compared with $654 (95% CI, $645-$663) for those without personal epinephrine” > “The value-based price (incremental cost-effectiveness ratio, $100 000 per quality-adjusted life-year) for personal epinephrine based on 10-fold fatality risk difference was $24.” > “At a market cost of $715 per twin pack, the autoinjector incremental cost-effectiveness ratio was $2 742 697 per quality-adjusted life-year.” > “If a hypothetical fatality risk protection from personal epinephrine was modeled at 100-fold, the value-based price ceiling for a personal autoinjector was $264.” Source: [Shaker and Greenhawt (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6324395/) #### Universal prescription of two epinephrine autoinjectors versus risk-stratified prescription in peanut allergy, United States and United Kingdom: Shaker et al. (2021a) Relevance: Evaluates universal prescription of two epinephrine autoinjectors against risk-stratified prescription in peanut allergy from United States and United Kingdom perspectives, addressing the two-device prescribing that the EpiPen and neffy labels in section 2 recommend. > “To evaluate the cost-effectiveness of routinely prescribing all patients 2 EAI devices versus a risk-stratified approach (2 EAIs prescribed only for patients with a risk factor).” > “Markov models compared universal versus risk-stratified approaches on the basis of either a previous medical history of anaphylaxis (PMH-ana) or anaphylaxis requiring multiple epinephrine doses (multi-epi).” > “Cohorts of children with peanut allergy were evaluated over an 80-year time horizon from both US and UK societal and health care perspectives.” > “Cost-effectiveness threshold was $100,000/quality-adjusted life-year (QALY).” > “From a US perspective, universal prescription of 2 EAIs to all patients with peanut allergy was not cost-effective in the base case versus risk stratification by PMH-ana.” > “Universal prescription of 2 EAIs was associated with an incremental cost of $10,696,036/QALY versus the PMH-ana strategy, and $17,514,558/QALY versus the multi-epi strategy.” > “From a UK perspective, universally prescribing 2 EAIs was also not cost-effective (incremental cost of $4,132,440/QALY vs PMH-ana and $6,208,227/QALY vs multi-epi) at single device costs more than $18.” Source: [Shaker et al. (2021a)](https://pubmed.ncbi.nlm.nih.gov/33486143/) #### Undesignated school stock epinephrine (supplemental and universal models) versus no school supply for peanut anaphylaxis, United States: Shaker and Greenhawt (2019a) Relevance: Evaluates undesignated stock epinephrine auto-injector supplies in schools for peanut anaphylaxis in the United States, one of the stock epinephrine settings that section 4.1 summarizes. > “Markov simulations of the Chicago Public Schools system were used over extended time horizons to model 2 school stock epinephrine autoinjector policies to provide access for at-risk students.” > “This study compared the following 3 strategies: no school undesignated epinephrine supply, school undesignated supplemental epinephrine supply (supplemental model), and school undesignated universal epinephrine supply (universal model).” > “Costs of school stock epinephrine units available for acquisition by schools were evaluated from a societal perspective.” > “Costs and quality-adjusted life-years (QALYs) were discounted equally at 3% per annum.” > “Based on Markov simulations of the Chicago Public Schools system (371 382 students), the cost was $107 816 (95% CI, $107 382-$108 250) for no school undesignated epinephrine supply compared with $108 160 (95% CI, $107 725-$108 595) for the supplemental model and $100 397 (95% CI, $99 979-$100 815) for the universal model.” > “When comparing supplemental model stock epinephrine to the strategy without undesignated devices, the incremental cost-effectiveness ratio was high at $268 811 per QALY in the base-case simulation.” > “The universal model dominated all others and was associated with significant cost savings ($7419 per student at risk who would otherwise be prescribed an individual school epinephrine supply).” Source: [Shaker and Greenhawt (2019a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439603/) #### Supplemental stock epinephrine autoinjectors versus ampule-only medical kits on commercial aircraft for food allergy, United States: Shaker and Greenhawt (2019b) Relevance: Evaluates stock epinephrine auto-injectors on commercial aircraft, a stock epinephrine setting that section 4.1 summarizes. > “We conducted a Markov model with microsimulation of food-allergic individuals over an 80-year time horizon to evaluate the cost-effectiveness of supplementing airline medical kits with epinephrine autoinjectors (eg, providing autoinjector twin-packs in addition to the epinephrine ampule in the medical kit), versus not doing so, using a per-plane annual value-based cost ceiling of $338 (the value-based ceiling for school stock epinephrine).” > “We assumed that autoinjector availability reduced fatality risk by 10%.” > “Equipping all commercial aircraft with autoinjectors cost $2,470,422/year ($0.08/passenger-at-risk), from a societal perspective and when distributed over all at-risk travelers.” > “Over the model horizon, the supplemental autoinjector strategy cost $32,329.29 (standard deviation [SD], $4024.32) versus $32,326.70 (SD $4024.29), produced 26.8917 quality-adjusted life-years (QALYs) (SD, 2.9720) versus 26.8915 (SD, 2.9725), with a lower fatality rate (0.00012; SD, 0.01095 vs 0.00015; SD, 0.1225) versus the ampule-only strategy.” > “The incremental cost-effectiveness ratio of supplemental airline epinephrine autoinjectors was $10,766/QALY in the base-case analysis.” Source: [Shaker and Greenhawt (2019b)](https://pubmed.ncbi.nlm.nih.gov/31201119/) #### Watchful waiting versus immediate emergency department transfer after epinephrine autoinjector use in children with food allergy, Canada: Yin et al. (2025) Relevance: Evaluates watchful waiting against immediate emergency department transfer after epinephrine auto-injector use for anaphylaxis in Canada, the post-administration management a model of community epinephrine use would include. > “We developed a probabilistic Markov model of individuals starting at age of one year who are at risk of severe food-related allergic reactions requiring epinephrine.” > “We evaluated medical costs (in 2022 Canadian dollars) and quality-adjusted life years (QALY) of each strategy over a 20-year horizon.” > “In the base case, we assumed a tenfold increase in food allergy fatality for patients under watchful waiting, which we increased to 100- to 1,000-fold in sensitivity analysis.” > “The analysis was conducted from the Canadian healthcare system perspective with a 1.5% annual discount rate and a willingness-to-pay (WTP) threshold of $50,000 per QALY.” > “Watchful waiting resulted in cost savings of $1,157 per patient” > “an incremental cost per QALY saved of $1,589,854. The incremental cost per death prevented with immediate ED transfer was $12,586,613.” > “Watchful waiting remained cost-effective in all sensitivity and scenario analyses, except under extreme increases in fatality risk of 500-fold and 1,000-fold.” Source: [Yin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11755952/) ### 1.3 The same disease in other populations or settings #### Universal versus contextual self-injectable epinephrine for patients receiving allergen immunotherapy, United States: Sun et al. (2019) Relevance: Evaluates universal against contextual prescribing of self-injectable epinephrine to patients receiving allergen immunotherapy in the United States, a population at risk of systemic allergic reactions. Access: Not open access Not quoted: The results are reported in the full text, which is closed access. > “An economic evaluation using cohort and microsimulation was performed from both the societal and health care sector perspectives for patients undergoing AIT, assessing a universal requirement to fill SIE prescriptions at the outset of therapy compared with requiring this only after a systemic reaction to immunotherapy (SRIT).” > “A universal SIE requirement for AIT is not cost-effective, with the incremental cost-effectiveness ratio for this strategy estimated at $669,327,730 per quality-adjusted life-year (QALY).” > “In the microsimulation (n = 10,000), the mean (SD) costs of a universal approach exceeded that of a more context-specific strategy where SIE was only prescribed for patients after an initial SRIT ($19,653.36 [$4296.66] vs $16,232.14 [$5204.32]), and given the effects on rates of AIT discontinuation, the universal approach was less effective (mean [SD], 25.555 [2.285] QALYs) compared with a contextualized approach (mean [SD], 25.579 [2.345] QALYs).” > “Universal SIE prescription could be cost-effective if it provided a 1000 times protection against AIT fatality at a value-based cost of $24, and the annual AIT fatality rates unrealistically exceed 2.6 per 10,000 patients.” Source: [Sun et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31520771/) #### Preemptive epinephrine before symptoms versus epinephrine for symptoms in children with peanut allergy, United States: Shaker and Greenhawt (2018b) Relevance: Evaluates preemptive epinephrine for any peanut exposure before symptoms against epinephrine for symptoms in children with peanut allergy in the United States, the timing question that the guideline recommendations in section 2 address. Access: Not open access Not quoted: The results are reported in the full text, which is closed access. > “The objective of this study was to assess the health and economic benefits of pre-emptively injecting epinephrine for peanut ingestion in the absence of any symptoms, and to avoid products with peanut precautionary allergen labeling (PAL).” > “We used Markov modeling and simulations, assuming a base-case 10-fold fatality risk increase for less conservative management, with sensitivity analysis investigating 100- to 1000-fold increased fatality risk, incorporating risks of accidental exposures, reactions, fatality, and family costs of food allergy.” > “Based on these assumptions, small reductions in per-patient fatality risk resulted from pre-emptive epinephrine injection without symptoms present (<1 × 10-4 fewer per-patient fatalities), with incremental costs of $1193 per patient, $11,681,501/life year saved, and $110,270,820/death prevented versus waiting for symptoms before use, but this was not cost-effective even assuming 1000-fold risk ($107, 971/quality of life adjusted year) or quality of life (QoL).” > “Commonly recommended practices of pre-emptive epinephrine injection in the absence of symptoms, or universal avoidance of PAL, were not cost-effective when compared with administering epinephrine on symptom development or allowing PAL consumption.” Source: [Shaker and Greenhawt (2018b)](https://pubmed.ncbi.nlm.nih.gov/29751153/) #### AR101 oral immunotherapy and Viaskin Peanut versus peanut avoidance in peanut allergy, United States: ICER (2019) Relevance: A United States health technology assessment that evaluates peanut oral immunotherapy and epicutaneous immunotherapy against peanut avoidance, the allergen immunotherapy and trigger avoidance strategies section 2 lists for preventing food-induced anaphylaxis. > “The primary aim of this analysis was to estimate the lifetime cost-effectiveness of the two peanut allergy immunotherapies from a US health care sector perspective.” > “Health states and transitions among them are modeled using a Markov model approach” > “All costs and outcomes were discounted at 3% per year.” > “Using the available placeholder price, the total lifetime cost was $72,000 for AR101 versus $6,000 for avoidance alone, and the incremental cost-effectiveness ratio was $88,000.” > “Immunotherapy with AR101 resulted in increased QALYs due to the utility benefit of more patients having peanut desensitization, with 0.75 incremental QALYs versus avoidance alone (Table 4.13).” > “Using the available placeholder price, the total cost was $62,000 for Viaskin Peanut versus $6,000 for avoidance alone, and the incremental cost- effectiveness ratio was $216,000.” > “Immunotherapy with Viaskin Peanut resulted in increased QALYs due to the utility benefit of increased peanut desensitization, with 0.26 incremental QALYs versus avoidance alone (Table 4.14).” > “Annual Cost to Achieve $100,000 per QALY Annual Cost to Achieve $150,000 per QALY AR101 $4,808 $7,248 Viaskin Peanut $3,010 $4,513” Source: [ICER (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_PeanutAllergy_Final_Report_071019.pdf) #### Omalizumab versus no omalizumab for food allergy in infants, United States: Shaker et al. (2024) Relevance: Evaluates omalizumab against no omalizumab in infants with food allergy in the United States from a societal perspective, a preventive therapy for people who carry epinephrine for food-induced anaphylaxis. Access: Not open access Not quoted: The results are reported in the full text, which is closed access. > “We evaluated health and economic outcomes in Markov cohorts of simulated food allergic infants randomized to receive omalizumab using a 15-year horizon.” > “Monte Carlo simulation was used (n = 40,000 subjects) to evaluate cost-effectiveness from a societal perspective, incorporating both a family-level and individual-level analysis.” > “In the family-level cohort analysis, omalizumab exceeded cost-effectiveness thresholds ($185,183/quality-adjusted life-years [QALY]).” > “In a comparison of the omalizumab strategy (OMA) with the non-omalizumab strategy, the cost of OMA exceeded the non-omalizumab strategy ($315,020 vs $136,609) with greater incremental effectiveness (12.668 vs 11.699 QALY).” > “In the individual-level analysis, the cost-effectiveness of OMA was $573,698/QALY.” > “The value-based cost of OMA ranged from $14,166 to $23,791 when it was considered at the individual and family-unit levels.” Source: [Shaker et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38925250/) #### Preschool peanut oral immunotherapy versus no immunotherapy in peanut allergy, United States and Canada: Shaker et al. (2021b) Relevance: Evaluates preschool peanut oral immunotherapy, an allergen immunotherapy that section 2 lists for food-induced anaphylaxis, against no immunotherapy in the United States and Canada from a societal perspective. > “Markov cohort analyses and microsimulation was used to evaluate simulated preschool children with PA over an 80-year time horizon.” > “Models incorporated the natural history of PA, comparing children treated with preschool POIT with those not receiving immunotherapy. Costs were expressed in U.S. and Canadian dollars.” > “A preschool POIT strategy was associated with cost savings while improving quality-adjusted life-years (QALY), dominating a nonimmunotherapy approach.” > “Over the model horizon, when all costs (and effectiveness) of PA were included from a societal perspective, a POIT versus a non-POIT approach cost $82,514 (18.51 QALY) versus $84,367 (17.75 QALY) in the United States, and $40,111 (18.83 QALY) versus $53,848 (18.26 QALY) in Canada.” Source: [Shaker et al. (2021b)](https://pubmed.ncbi.nlm.nih.gov/33744474/) ### 1.4 Related diseases and analogous treatments No evidence found. ## 2 Utility weights ### 2.1 Utility weights from analyses of Anaphylm (dibutepinephrine and AQST-109) No evidence found. ### 2.2 Utility weights for the same indication No evidence found. ### 2.3 Utility weights for the same disease in other populations or settings #### Utility weights for moderate and severe allergic reactions, food allergy, and anaphylaxis, peanut allergy: Shaker et al. (2021a) Relevance: Utilities for moderate and severe allergic reactions in peanut allergy and disutilities for food allergy and for a transient episode of anaphylaxis, from a United States and United Kingdom model of epinephrine autoinjector prescribing. Access: Not open access Not quoted: The utility weights are reported in the full text, which is closed access. Source: [Shaker et al. (2021a)](https://pubmed.ncbi.nlm.nih.gov/33486143/) #### Utility weights for peanut allergy, anaphylaxis, and oral immunotherapy, peanut allergy: Shaker et al. (2021b) Relevance: Utility weights for peanut allergy, anaphylaxis, and oral immunotherapy, from a United States and Canadian model of preschool peanut oral immunotherapy. Access: Not open access Not quoted: The utility weights are reported in the full text, which is closed access. > “Models incorporated the natural history of PA, comparing children treated with preschool POIT with those not receiving immunotherapy.” Source: [Shaker et al. (2021b)](https://pubmed.ncbi.nlm.nih.gov/33744474/) #### Baseline utility weight, peanut allergy: Shaker et al. (2025) Relevance: Baseline utility for peanut allergy used in the model of non-injectable against intramuscular epinephrine. Access: Not open access Not quoted: The utility weights are reported in the full text, which is closed access. > “Markov cohort analyses evaluated the cost-effectiveness of noninjectable epinephrine forms.” Source: [Shaker et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39637974/) #### Disutility for food allergy, peanut allergy in school-age children: Shaker and Greenhawt (2019a) Relevance: Disutility for food allergy, from a United States model of school stock epinephrine for peanut anaphylaxis. > “Negative health state consequence for food allergy −0.09 (sensitivity, −0.02 to −.11)” Source: [Shaker and Greenhawt (2019a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439603/) #### Utility weights for peanut sensitivity, desensitization, and tolerance by age, peanut allergy: ICER (2019) Relevance: EQ-5D utilities for peanut sensitivity, desensitization, and tolerance in children and in adolescents and adults, from a United States health technology assessment. > “The estimates of utility were derived using parent-reported (for children) and adolescent-reported EuroQol-5-Dimension (EQ-5D) responses.” Source: [ICER (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_PeanutAllergy_Final_Report_071019.pdf) | Health state | Utility | | --- | --- | | “Children (Age 0-11) Treatment or Avoidance Alone with Peanut Sensitivity” | “0.840” | | “Children (Age 0-11) Treatment or Avoidance Alone with Peanut Desensitization” | “0.900” | | “Children (Age 0-11) Peanut Tolerant” | “0.940” | | “Adolescents/Adults (Age 12+) Treatment or Avoidance Alone with Peanut Sensitivity” | “0.910” | | “Adolescents/Adults (Age 12+) Treatment or Avoidance Alone with Peanut Desensitization” | “0.964” | | “Adolescents/Adults (Age 12+) Peanut Tolerant” | “1.0” | Source: [ICER (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_PeanutAllergy_Final_Report_071019.pdf) > “Assumption that participants in the peanut desensitized health state received the average of the utilities for the untreated with peanut sensitivity and peanut tolerant health states.” Source: [ICER (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_PeanutAllergy_Final_Report_071019.pdf) #### Utility weights for food allergy and peanut oral immunotherapy, peanut allergy in children: Shaker (2017) Relevance: Utility weights for food allergy and for peanut allergy on oral immunotherapy in children, from a model of peanut oral immunotherapy. Access: Not open access Not quoted: The utility weights are reported in the full text, which is closed access. > “Cohort simulations were used to evaluate the effect of POIT for children with peanut allergy.” Source: [Shaker (2017)](https://pubmed.ncbi.nlm.nih.gov/28606784/) #### Disutility for anaphylaxis, second Tdap vaccine dose: Kamiya et al. (2016) Relevance: Disutility for an episode of anaphylaxis, from a model of a second Tdap vaccine dose in which anaphylaxis is an adverse event. Access: Not open access Not quoted: The utility weights are reported in the full text, which is closed access. > “A static cohort model was used to calculate the epidemiologic and economic impact of adding a second dose of Tdap at age 16 or 21 years.” > “Quality-adjusted Life Years (QALY) saved were calculated.” Source: [Kamiya et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26899377/) #### Disutility for anaphylaxis, routine annual influenza vaccination: Kim DeLuca et al. (2023) Relevance: Disutility for anaphylaxis, from a United States influenza vaccination model in which anaphylaxis is an adverse event. Access: Full text not retrieved Not quoted: The utility weights are reported in the full text, which this page does not quote. > “A state transition simulation model was constructed to estimate the health and economic outcomes of influenza vaccination compared to no vaccination for hypothetical US cohorts stratified by age and risk status.” Source: [Kim DeLuca et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37291022/) #### Utility weight for hospitalization with anaphylaxis, pneumococcal vaccination in healthy younger adults: Pepper and Owens (2002) Relevance: Utility for a hospitalization with anaphylaxis, from a vaccination model in which anaphylaxis is an adverse event. Access: Not open access Not quoted: The utility weights are reported in the full text, which is closed access. > “The authors developed a decision model to compare the health and economic outcomes of vaccinate versus do not vaccinate for S. pneumoniae.” Source: [Pepper and Owens (2002)](https://pubmed.ncbi.nlm.nih.gov/12369231/) ### 2.4 Utility weights for related diseases and analogous treatments No evidence found. ## 3 Search strategy | Dataset | Query | Results | | --- | --- | --- | | Methods | dibutepinephrine OR Anaphylm OR "AQST-109" | 0 | | Ratios | epinephrine OR adrenaline | 23 | | Ratios | anaphylaxis OR anaphylactic OR autoinjector OR "auto-injector" | 24 | | Ratios | "peanut allergy" OR "food allergy" OR "peanut anaphylaxis" | 34 | | Ratios | venom OR hymenoptera OR "insect sting" | 0 | | Weights | anaphylaxis OR anaphylactic OR "allergic reaction" | 50 | | Methods | epinephrine OR adrenaline OR anaphylaxis | 21 | | Ratios | neffy OR "nasal epinephrine" OR "intranasal epinephrine" OR "sublingual epinephrine" | 2 | | Weights | "food allergy" OR "peanut allergy" | 36 | ## Related pages - [Anaphylm (dibutepinephrine): Type I allergic reactions including anaphylaxis](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis.md) - [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Terms and abbreviations](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/terms-and-abbreviations.md) - [Anaphylm (dibutepinephrine): Type I allergic reactions including anaphylaxis](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/executive-summary.md) - [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Product information and disease description](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/product-information-and-disease-description.md) - [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Clinical evidence](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/clinical-evidence.md) - [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Economic information and modeling report](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/economics) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/economics.md) - [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: References](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/references) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/references.md) - [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: prevalence by geography](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/prevalence) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/prevalence.md)